607 related articles for article (PubMed ID: 30598575)
1. Hepatitis C: From inflammatory pathogenesis to anti-inflammatory/hepatoprotective therapy.
Li H; Huang MH; Jiang JD; Peng ZG
World J Gastroenterol; 2018 Dec; 24(47):5297-5311. PubMed ID: 30598575
[TBL] [Abstract][Full Text] [Related]
2. What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection?
Ioannou GN; Feld JJ
Gastroenterology; 2019 Jan; 156(2):446-460.e2. PubMed ID: 30367836
[TBL] [Abstract][Full Text] [Related]
3. Enhanced immune responses, PI3K/AKT and JAK/STAT signaling pathways following hepatitis C virus eradication by direct-acting antiviral therapy among Egyptian patients: a case control study.
Ramadan HK; Badr G; Ramadan NK; Sayed A
Pathog Dis; 2021 Mar; 79(3):. PubMed ID: 33524139
[TBL] [Abstract][Full Text] [Related]
4. Levels of Cytokines in Serum Associate With Development of Hepatocellular Carcinoma in Patients With HCV Infection Treated With Direct-Acting Antivirals.
Debes JD; van Tilborg M; Groothuismink ZMA; Hansen BE; Schulze Zur Wiesch J; von Felden J; de Knegt RJ; Boonstra A
Gastroenterology; 2018 Feb; 154(3):515-517.e3. PubMed ID: 29102620
[TBL] [Abstract][Full Text] [Related]
5. Rewiring Host Signaling: Hepatitis C Virus in Liver Pathogenesis.
Virzì A; Roca Suarez AA; Baumert TF; Lupberger J
Cold Spring Harb Perspect Med; 2020 Jan; 10(1):. PubMed ID: 31501266
[TBL] [Abstract][Full Text] [Related]
6. The Path to Cancer and Back: Immune Modulation During Hepatitis C Virus Infection, Progression to Fibrosis and Cancer, and Unexpected Roles of New Antivirals.
Debes JD; de Knegt RJ; Boonstra A
Transplantation; 2017 May; 101(5):910-915. PubMed ID: 28045877
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis.
Khatun M; Ray RB
Cells; 2019 Oct; 8(10):. PubMed ID: 31615075
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals.
Perez S; Kaspi A; Domovitz T; Davidovich A; Lavi-Itzkovitz A; Meirson T; Alison Holmes J; Dai CY; Huang CF; Chung RT; Nimer A; El-Osta A; Yaari G; Stemmer SM; Yu ML; Haviv I; Gal-Tanamy M
PLoS Genet; 2019 Jun; 15(6):e1008181. PubMed ID: 31216276
[TBL] [Abstract][Full Text] [Related]
9. Persistent Hepatic Inflammation Plays a Role in Hepatocellular Carcinoma After Sustained Virological Response in Patients with HCV Infection.
Nirei K; Kanda T; Nakamura H; Matsuoka S; Takayama T; Sugitani M; Moriyama M
Int J Med Sci; 2018; 15(5):466-474. PubMed ID: 29559835
[No Abstract] [Full Text] [Related]
10. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows.
Guarino M; Sessa A; Cossiga V; Morando F; Caporaso N; Morisco F;
World J Gastroenterol; 2018 Jun; 24(24):2582-2595. PubMed ID: 29962815
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis in hepatitis C virus infection.
Bantel H; Schulze-Osthoff K
Cell Death Differ; 2003 Jan; 10 Suppl 1():S48-58. PubMed ID: 12655346
[TBL] [Abstract][Full Text] [Related]
12. Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradication.
Motoyama H; Tamori A; Kubo S; Uchida-Kobayashi S; Takemura S; Tanaka S; Ohfuji S; Teranishi Y; Kozuka R; Kawamura E; Hagihara A; Morikawa H; Enomoto M; Murakami Y; Kawada N
PLoS One; 2018; 13(3):e0194163. PubMed ID: 29534101
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?
Meringer H; Shibolet O; Deutsch L
World J Gastroenterol; 2019 Aug; 25(29):3929-3940. PubMed ID: 31413528
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.
Adhoute X; Penaranda G; Raoul JL; Sellier F; Castellani P; Oules V; Perrier H; Lefolgoc G; Pol B; Campanile M; Bayle O; Beaurain P; Monnet O; Bourlière M
Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):368-375. PubMed ID: 29384796
[TBL] [Abstract][Full Text] [Related]
15. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.
Kanwal F; Kramer J; Asch SM; Chayanupatkul M; Cao Y; El-Serag HB
Gastroenterology; 2017 Oct; 153(4):996-1005.e1. PubMed ID: 28642197
[TBL] [Abstract][Full Text] [Related]
16. Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside.
Rockey DC; Friedman SL
Gastroenterology; 2021 Apr; 160(5):1502-1520.e1. PubMed ID: 33529675
[TBL] [Abstract][Full Text] [Related]
17. The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma.
Wirth TC; Manns MP
Ann Oncol; 2016 Aug; 27(8):1467-74. PubMed ID: 27226385
[TBL] [Abstract][Full Text] [Related]
18. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study.
Ferrarese A; Germani G; Gambato M; Russo FP; Senzolo M; Zanetto A; Shalaby S; Cillo U; Zanus G; Angeli P; Burra P
World J Gastroenterol; 2018 Oct; 24(38):4403-4411. PubMed ID: 30344424
[TBL] [Abstract][Full Text] [Related]
20. Urinary metabolomics of HCV patients with severe liver fibrosis before and during the sustained virologic response achieved by direct acting antiviral treatment.
Biliotti E; Giampaoli O; Sciubba F; Marini F; Tomassini A; Palazzo D; Capuani G; Esvan R; Spaziante M; Taliani G; Miccheli A
Biomed Pharmacother; 2021 Nov; 143():112217. PubMed ID: 34560544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
